Expression in childhood primary brain tumors of NY-ESO-1, a cancer/testis antigen: An immunohistochemical study

In Vivo

Volumn 22, Issue 1, 2008, Pages 83-88

  Bodey, Bela ^a,b,c   Bodey, Vivian ^a,b   Siegel, Stuart E ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c NONE   (United States)

Author keywords

Antigen retrieval; ASTR; Cancer testis antigens; Childhood astrocytoma; Childhood medulloblastoma; CTAs; Immunocytochemistry; Immunophenotype; IP; MED; MoAB; Monoclonal antibody; NAMs; Neoplasm associated markers; NY ESO 1; TIL; Tumor infiltrating lymphocytes

Indexed keywords

ALKALINE PHOSPHATASE; NY ESO 1 ANTIGEN;

ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CANCER INFILTRATION; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALIGNANT NEOPLASTIC DISEASE; MEDULLOBLASTOMA; NEUROECTODERM TUMOR; NEUROPATHOLOGY;

EID: 40749122515     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Chen YT, Scanlan MI, Sahin U, Tureci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M and Old LJ: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 94: 1914-1918, 1997.
2. Sahin U, Tureci O, Chen YT, Seitz G, Villena-Heinsen C, Old LJ and Pfreundschuh M: Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: basis for polyvalent CT vaccine strategies. Int J Cancer 78: 387-389, 1998.
3. Scanlan MJ, Altorki NK, Gure AO, Williamson B, Jungbluth A, Chen YT and Old LJ: Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9. Cancer Lett 150: 155-164, 2000.
4. Lee SY, Obata Y, Yoshida M, Stockert E, Williamson B, Jungbluth AA, Chen YT, Old LJ and Scanlan MJ: Immunomic analysis of human sarcoma. Proc Natl Acad Sci USA 100: 2651-2656, 2003.
5. Chen CH, Chen GJ, Lee HS, Huang GT, Yang PM, Tsai LJ, Chen DS and Sheu JC: Expressions of cancer-testis antigens in human hepatocellular carcinomas. Cancer Lett 164: 189-195, 2001.
6. Luo G, Huang S, Xie X, Stockert E, Chen YT, Kubuschok B and Pfreundschuh M: Expression of cancer-testis genes in human hepatocellular carcinomas. Cancer Immun 2: 11, 2002.
7. + T-cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci USA 100: 8862-8867, 2003.
8. Lee L, Wang RF, Wang X, Mixon A, Johnson BE, Rosenberg SA and Schrump DS: NY-ESO-1 may be a potential target for lung cancer immunotherapy. Cancer J Sci Am 5: 20-25, 1999.
9. Lu Y, Wu LQ, Lü ZH, Wang XJ and Yang JY: Expression of SSX-1 and NY-ESO-1 mRNA in tumor tissues and its corresponding peripheral blood expression in patients with hepatocellular carcinoma. Chin Med J (Engl) 120: 1042-1046, 2007.
10. Stockert E, Jager E, Chen YT, Scanlan MJ, Gout I, Karbach J, Arand M, Knuth A and Old LJ: A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 187: 1349-1354, 1998.
11. Jager E, Nagata Y, Gnjatic S, Wada H, Stockert E, Karbach J, Dunbar PR, Lee SY, Jungbluth A, Jager D, Arand M, Ritter G, Cerundolo V, Dupont B, Chen YT, Old LJ and Knuth A: Monitoring CD8 T-cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci USA 97: 4760-4765, 2000.
12. Jager D, Jager E and Knuth A: Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J Clin Pathol 54: 669-674, 2001.
13. Jager E, Stockert E, Zidianakis Z, Chen YT, Karbach J, Jager D, Arand M, Ritter G, Old LJ and Knuth A: Humoral immune responses of cancer patients against "cancer-testis" antigen NY-ESO-I: correlation with clinical events. Int J Cancer 84: 506-510, 1999.
14. Kurashige T, Noguchi Y, Saika T, Ono T, Nagata Y, Jungbluth A, Ritter G, Chen YT, Stockert E, Tsushima T, Kumon H, Old LJ and Nakayama E: NY-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. Cancer Res 61: 4671-4674, 2001.
15. Katsura S, Suzuki J and Wada T: Statistical study of brain tumours in the neurosurgical clinics in Japan. J Neurosurg 16: 570-580, 1959.
16. von Deimling A, Louis DN and Wiestler OD: Molecular pathways in the formation of gliomas. Glia 15: 328-338, 1995.
17. Kleihues P, Soylemezoglu F, Schauble B, Scheithauer BW and Burger PC: Histopathology, classification, and grading of gliomas. Glia 15: 211-221, 1995.
18. Williams BP, Abney ER and Raff MC: Macroglial cell development in embryonic rat brain: studies using monoclonal antibodies, flourescence-activated cell sorting and cell culture. Dev Biol 112: 126-134, 1985.
19. Biernat W, Tohma Y, Yonekawa Y, Kleihues P and Ohgaki H: Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathol 94: 303-309, 1997.
20. Bailey P and Cushing H: Medulloblastoma cerebelli, a common type of midcerebellar glioma of childhood. Arch Neurol Psychiatry 14: 192-224, 1925.
21. Bodey B, Bodey V, Siegel SE and Kaiser HE: Survivin expression in childhood medulloblastomas: a possible diagnostic and prognostic marker. In Vivo 18: 713-718, 2004.
22. Torres LF, Jacob GV, Reis-Filho JS and de Noronha L: Primary pediatric tumours of the central nervous system. Anatomopathological study of 623 cases. Arq Neuropsiquiatr 55: 795-800, 1997.
23. Zulch KJ: Principles of the new World Health Organization (WHO) classification of brain tumors. Neuroradiology 19: 59-66, 1980.
24. Szymas J: Histologic classification of central nervous system tumors by the World Health Organization. Pol J Pathol 45: 81-91, 1994.
25. Szymas J: Diagnostic immunohistochemistry of tumors of the central nervous system. Folia Neuropathol 32: 209-214, 1994.
26. Janckila AJ, Yam LT and Li C-Y: Immunoalkaline phosphatase cytochemistry. Am J Clin Pathol 84: 476-480, 1985.
27. Cattoretti G, Berti E, Schiro R, D'Amato L, Valeggio C and Rilke F: Improved avidin-biotin-peroxidase complex (ABC) staining. Histol J 20: 75-80, 1988.
28. Wilchek M and Bayer EA: Introduction to avidin-biotin technology. Methods Enzymol 184: 5-13, 1990.
29. Duhamel RC and Whitehead JS: Prevention of nonspecific binding of avidin. Methods Enzymol 184:. 201-207, 1990.
30. Diamandis EP and Christopoulos TK: The biotin-(strept)avidin system: principles and applications in biotechnology. Clin Chem 37: 625-636, 1991.
31. Bodey B, Bodey B Jr, Siegel SE and Kaiser HE: Immunocyto-chemical detection of the Homeobox B3, B4 and C6 gene products in childhood medulloblastomas/primitive neuroectodermal tumors. Anticancer Res 20: 1769-1780, 2000.
32. Bodey B, Bodey B Jr, Siegel SE and Kaiser HE: Fas (APO-1, CD95) receptor expression in childhood astrocytomas. Is it a marker of the major apoptotic pathway or a signaling receptor for immune escape of neoplastic cells? In Vivo 13: 357-373, 1999.
33. Bodey B, Bodey B Jr, Siegel SE and Kaiser HE: Matrix metalloproteinase expression in childhood medulloblastomas/primitive neuroectodermal tumors. In Vivo 14: 667-673, 2000.
34. Bodey B, Bodey B Jr, Siegel SE and Kaiser HE: Immunocyto-chemical detection of leukocyte-associated and apoptosis-related antigen expression in childhood brain tumors. Critical Reviews Oncology/Hemat 39: 3-16, 2001.
35. Bodey B: The significance of immunocytochemistry in the diagnosis and therapy of neoplasms. Expert Opinion Biological Therapy 2: 371-393, 2002.
36. Battifora H and Mehta P: The checkerboard tissue block. An improved multitissue control block. Lab Invest 63: 722-724, 1990.
37. Bodey B, Zeltzer PM, Saldivar V and Kemshead J: Immunophenotyping of childhood astrocytomas with a library of monoclonal antibodies. Int J Cancer 45: 1079-1087, 1990.
38. Bodey B: Cancer-testis antigens: promising targets for antigen directed antineoplastic immunotherapy. Expert Opin Biol Ther 2: 577-584, 2002.
39. Mashino K, Sadanaga N, Tanaka F, Yamaguchi H, Nagashima H, Inoue H, Sugimachi K and Mori M: Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br J Cancer 85: 713-720, 2001.
40. Sahin U, Koslowski M, Tureci O, Eberle T, Zwick C, Romeike B, Moringlane JR, Schwechheimer K, Feiden W and Pfreundschuh M: Expression of cancer testis genes in human brain tumors. Clin Cancer Res 6: 3916-3922, 2000.
41. Bodey B, Siegel SE and Kaiser HE: MAGE-1, a cancer/testis-antigen, expression in childhood astrocytomas as an indicator of tumor progression. In Vivo 16: 583-588, 2002.
42. Bodey B, Siegel SE and Kaiser HE: Immunocytochemical detection of members of the caspase cascade of apoptosis in high-grade astrocytomas. In Vivo 18: 593-602, 2004.
43. Clark J, Rocques PJ, Crew AJ, Gill S, Shipley J, Chan AM, Gusterson BA and Cooper CS: Identification of novel genes, SYT and SSX, involved in the t(x;18) (p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet 7: 502-508, 1994.
44. Jungbluth AA, Antonescu CR, Busam KJ, Iversen K, Kolb D, Coplan K, Chen YT, Stockert E, Ladanyi M and Old LJ: Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. Int J Cancer 94: 252-256, 2001.
45. Jager E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jager D, Arand M, Wada H, Noguchi Y, Stockert E, Old LJ and Knuth A: Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187: 265-70, 1998.
46. + CD25-CD8- T-cell clones. Cancer Immun 4: 15, 2004.
47. Velazquez EF, Jungbluth AA, Yancovitz M, Gnjatic S, Adams S, O'Neill D, Zavilevich K, Albukh T, Christos P, Mazumdar M, Pavlick A, Polsky D, Shapiro R, Berman R, Spira J, Busam K, Osman I and Bhardwaj N: Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM) - correlation with prognostic factors. Cancer Immun 7: 11, 2007.